Bimekizumab: the new drug in the biologics armamentarium for psoriasis

Article Page

Abstract

Bimekizumab, a humanized monoclonal IgG1 antibody being currently evaluated for multiple immune-mediated diseases, is mentioned in the recent report by Clarivate, Drugs to Watch in 2021, as one of the drugs to be observed in 2021. Due to its novel mechanism of action (dual inhibition of IL-17A and IL-17F), bimekizumab is considered a new therapeutic approach for the treatment of moderate-to-severe psoriasis. Bimekizumab has demonstrated superiority in all direct comparative clinical trials conducted, whether against ustekinumab (IL-12/23 inhibitor), adalimumab (TNF inhibitor) or secukinumab (IL-17A inhibitor), and has shown very encouraging results for the treatment of psoriatic arthritis. Since September 2020, the drug is being reviewed by the EMA and FDA for the treatment of psoriasis. Herein, the current status of bimekizumab is discussed.

Keywords: bimekizumab, IL-17, psoriasis, psoriatic arthritis.

Citation: Freitas E, Torres T. Bimekizumab: the new drug in the biologics armamentarium for psoriasis. Drugs in Context 2021; 10: 2021-4-1. DOI: 10.7573/dic.2021-4-1

Contributions: All the authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: EF has no conflicts of interest. TT is a scientific consultant/speaker/clinical study investigator for AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Fresenius Kabi Pharma, Janssen, Leo Pharma, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sandoz, Sanofi, UCB, Viatris. He is also an Associate Editor for Drugs in Context. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/05/dic.2021-4-1-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2021 Freitas E, Torres T. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Freitas E, Torres T. https://doi.org/10.7573/dic.2021-4-1. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/bimekizumab:-the-new-drug-in-the-biologics-armamentarium-for-psoriasis

Correspondence: Tiago Torres, Department of Dermatology, Centro Hospitalar do Porto, Rua D Manuel II, S/N, 4050-344, Porto, Portugal. Email: torres.tiago@outlook.com

Provenance: Invited; externally peer reviewed.

Submitted: 6 April 2021; Accepted: 11 May 2021; Publication date: 8 June 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF